Scopus Biopharma Inc SCPS Stock Analysis
- PINK
- Stock
- Market closed · opens Monday 9:30 AM ET
$0.00 unchanged at close Nov 5
Last close · Previous close $0.00
- Market cap
- At the Nov 5 close
- P/E ratio
- n/mLoss over last 12 months
- Diluted EPS
- −$0.32Last 12 months
- Dividend yield
- NoneLast 12 months
Price chart
$0.00unchangedThu, Nov 5 session
Use the left and right arrow keys to move along the chart.
Price data
Trading
- Previous close$0.00Nov 4
- Volume1.00Nov 5 session
Shares traded on all US exchanges in the last completed session. Live intraday volume covers IEX only, so it is left out.
- Avg. volume7.29KLast 21 sessions
The average daily shares traded over the last 21 trading sessions, about one calendar month.
- 52-week range: $0.00 to $0.00; now $0.00
The lowest and highest trades over the past 52 weeks, adjusted for splits. The marker shows the latest price.
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
Performance
Past performance, measured to the Nov 5 close. Total return includes reinvested dividends.Price change only, without dividends. Compared with the S&P 500, using SPY.
SCPS beat the S&P 500 in 1 of 6 periods.
| Period | SCPS and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | SCPS: down 33.3% S&P 500: down 5.4% | SCPS trailed the S&P 500 by 27.9 percentage points Trailed |
| 3M | SCPS: unchanged S&P 500: down 4.5% | SCPS beat the S&P 500 by 4.5 percentage points Beat |
| YTD | SCPS: unchanged S&P 500: up 8.3% | SCPS trailed the S&P 500 by 8.3 percentage points Trailed |
| 1Y | SCPS: unchanged S&P 500: up 9.3% | SCPS trailed the S&P 500 by 9.3 percentage points Trailed |
| Long term | ||
| 3Y | SCPS: down 99.1% S&P 500: up 74.8% −79.4% vs +20.5% a year | SCPS trailed the S&P 500 by 173.9 percentage points Trailed |
| 5Y | SCPS: down 100.0% S&P 500: up 67.3% −83.8% vs +10.8% a year | SCPS trailed the S&P 500 by 167.3 percentage points Trailed |
$10,000 invested in SCPS 5 years ago (Nov 5, 2021) would be worth about $1 at the close on , with dividends reinvested. The same amount in the S&P 500 would be worth about $16,730.
SCPS beat the S&P 500 in 1 of 6 periods.
| Period | SCPS and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | SCPS: down 33.3% S&P 500: down 5.4% | SCPS trailed the S&P 500 by 27.9 percentage points Trailed |
| 3M | SCPS: unchanged S&P 500: down 4.8% | SCPS beat the S&P 500 by 4.8 percentage points Beat |
| YTD | SCPS: unchanged S&P 500: up 7.5% | SCPS trailed the S&P 500 by 7.5 percentage points Trailed |
| 1Y | SCPS: unchanged S&P 500: up 8.2% | SCPS trailed the S&P 500 by 8.2 percentage points Trailed |
| Long term | ||
| 3Y | SCPS: down 99.1% S&P 500: up 68.6% −79.4% vs +19.0% a year | SCPS trailed the S&P 500 by 167.7 percentage points Trailed |
| 5Y | SCPS: down 100.0% S&P 500: up 56.4% −83.8% vs +9.4% a year | SCPS trailed the S&P 500 by 156.4 percentage points Trailed |
$10,000 invested in SCPS 5 years ago (Nov 5, 2021) would be worth about $1 at the close on , not counting dividends. The same amount in the S&P 500 would be worth about $15,645.
All-time high
$33.96
Closing high on . Now 100.0% below that record.
Split-adjusted daily closes since Dec 16, 2020.
Stock splits
SCPS hasn’t split since its price history begins in 2020.
Valuation
Financials
Reported results, not forecasts. From company filings via Tiingo; the latest report is Q2 FY23, the quarter ended Jun 30, 2023. “Last 12 months” means the four quarters from Jul 1, 2022 to Jun 30, 2023, and balance-sheet figures are as of Jun 30, 2023.
Revenue and net income
Last 12 months, with the change from the 12 months before
- Revenue
- $0.00
- Net income
- −$8.70M
- Diluted EPS
- −$0.32
Data table
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| Q3 FY21 (Sep 30, 2021) | $0.00 | −$1.40M | −$0.08 |
| Q4 FY21 (Dec 31, 2021) | $0.00 | −$6.52M | −$0.33 |
| Q1 FY22 (Mar 31, 2022) | $0.00 | −$4.66M | −$0.22 |
| Q2 FY22 (Jun 30, 2022) | $0.00 | −$3.32M | −$0.16 |
| Q3 FY22 (Sep 30, 2022) | $0.00 | −$1.90M | −$0.09 |
| Q4 FY22 (Dec 31, 2022) | $0.00 | −$1.73M | −$0.08 |
| Q1 FY23 (Mar 31, 2023) | $0.00 | −$2.45M | −$0.08 |
| Q2 FY23 (Jun 30, 2023) | $0.00 | −$2.62M | −$0.07 |
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| FY20 (Dec 31, 2020) | $0.00 | −$10.86M | −$0.81 |
| FY21 (Dec 31, 2021) | $0.00 | −$26.95M | −$1.56 |
| FY22 (Dec 31, 2022) | $0.00 | −$11.61M | −$0.55 |
Margins
- Gross —
- Operating —
- Net —
The percentages above the chart cover the last 12 months; the lines show each quarter. What margins tell you
Cash flow
- −$3.04MLast 12 months
Cash from operations minus capital spending: the cash left after the business maintains and grows its assets.
FCF = Operating cash flow − Capital spendingFree cash flow - Operating cash flow−$3.04MLast 12 months
- Capital spending$0.00Last 12 months
Shareholder returns
- $1.97MLast 12 months
Cash spent repurchasing shares, net of shares issued. Buybacks shrink the share count, so each remaining share owns more of the company.
- Dividends paid$0.00Last 12 months
- Total returned$0.00Last 12 months
Balance sheet
- $362.10KAs of Jun 30, 2023
Cash plus short- and long-term marketable securities on the Jun 30, 2023 balance sheet.
- Total debt$0.00As of Jun 30, 2023
- Net cash$362.10KAs of Jun 30, 2023
- 0.05As of Jun 30, 2023
Current assets divided by current liabilities on the Jun 30, 2023 balance sheet. Above 1 means short-term assets cover the bills due within a year.
Current ratio = Current assets ÷ Current liabilitiesCurrent ratio
Financial strength
- −1,195.8%Last 12 months
Over the last 12 months, Scopus Biopharma’s net loss was 1,195.8% of its total assets (averaged over the last four quarter-ends).
ROA = Net income (last 12 months) ÷ Average total assets
About Scopus Biopharma Inc
Scopus Biopharma Inc
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- New York, USA
- SEC filings
- EDGAR (opens in a new tab)
- Exchange
- PINK
- Asset type
- Common stock
- Price history since
SCPS news
Explore more stocks
Prices are from the last refresh. Open any stock for its live dashboard.
Popular stocks
SCPS stock FAQ
What is SCPS stock’s price today?
Scopus Biopharma (SCPS) traded at $0.00 at the close on , unchanged from the previous close of $0.00. Over the past 52 weeks it has traded between $0.00 and $0.00.
If you invested $1,000 in SCPS 5 years ago, how much would you have now?
With dividends reinvested, $1,000 invested in SCPS on would be worth about $0 at the close on , a total return of −100.0%. The same $1,000 would be worth $1,000 if invested one year ago. Past performance doesn’t predict future returns.
What is SCPS’s P/E ratio?
SCPS’s P/E ratio isn’t meaningful right now because its earnings over the four quarters to are negative (diluted EPS of −$0.32).
What are SCPS’s earnings per share?
SCPS’s diluted earnings per share were −$0.32 over the four quarters to , compared with −$0.79 in the twelve months before. The latest quarter (Q2 FY23) brought −$0.07 per share, against −$0.16 a year earlier (how EPS works).
Does SCPS pay a dividend?
Scopus Biopharma hasn’t paid a dividend in the last twelve months.
What is SCPS’s 52-week high and low?
Over the past 52 weeks SCPS has traded as low as $0.00 and as high as $0.00. At $0.00 at the close on , it is 33.3% below that high and 39,900.0% above the low.
What is SCPS’s all-time high?
SCPS’s highest closing price was $33.96 on , adjusted for stock splits. At $0.00 at the close on , it is 100.0% below that record.
Has SCPS stock ever split?
No. SCPS hasn’t split since its price history begins in 2020.
How has SCPS stock performed?
Including dividends and measured to the close on , SCPS has returned 0.0% so far this year and 0.0% over the past year, and −100.0% over five years (−83.8% a year). Over the same periods the S&P 500, measured by SPY, returned +8.3%, +9.3% and +67.3%. Past performance doesn’t predict future returns.
What sector and industry is Scopus Biopharma in?
Scopus Biopharma is in the Healthcare sector and the Biotechnology industry, and is headquartered in New York, USA.
What exchange does SCPS trade on?
Scopus Biopharma trades on the PINK under the ticker symbol SCPS. Its price history on this dashboard begins on .
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
About this data. Data sourced by Tiingo (opens in a new tab). The live price is Tiingo’s real-time price, based on IEX trades and quotes; intraday charts show IEX trades, and volume figures are consolidated totals for completed sessions. Prices are split-adjusted, and total returns assume dividends are reinvested. Financials come from company filings and can lag new reports. Times are Eastern.
This page is for education, not investment advice. Past performance doesn't predict future returns. Logos provided by Logo.dev (opens in a new tab).
The Interactive Brokers word and logo are trademarks of Interactive Brokers LLC (or its subsidiaries) in the US and/or elsewhere. All rights reserved.